ArcticZymes Embarks on Biomanufacturing Enzyme Project
Company Announcements

ArcticZymes Embarks on Biomanufacturing Enzyme Project

ArcticZymes Technologies ASA (DE:B4V) has released an update.

ArcticZymes Technologies ASA has initiated the AdEPT project, in collaboration with The Research Council of Norway, the University of Tromsø, and SINTEF Industri, with a funding of up to 11.8 MNOK to develop novel enzyme solutions for advanced therapy biomanufacturing. The project aims to tackle challenges in the production and analysis of therapeutic RNA, crucial for the cell and gene therapy sectors. CEO Michael B. Akoh expresses his commitment to enhancing the company’s enzyme portfolio and anticipates the project’s contribution to new therapeutic modalities.

For further insights into DE:B4V stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskArcticZymes Chairman Increases Stake, Boosting Investor Confidence
TipRanks European Auto-Generated NewsdeskArcticZymes Showcases Enzyme Innovations at ESGCT 2024
TipRanks European Auto-Generated NewsdeskArcticZymes Showcases Growth and Innovation at Healthcare Conference
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App